Effect of meso-2,3-dimercaptosuccinic acid on urinary lead excretion in exposed men

The efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) was evaluated in workers occupationally exposed to lead (Pb; blood level >50 mg //dL). Ten men were given 600 mg of DMSA per orem daily, for five days. Pb concentrations of whole blood and urine were determined throughout therapy. Hematology...

Full description

Saved in:
Bibliographic Details
Published in:Human & experimental toxicology 2002-11, Vol.21 (11), p.573-577
Main Authors: Torres-Alanís, O, Garza-Ocañas, L, Piñeyro-López, A
Format: Article
Language:English
Subjects:
Acids
Administration, Oral
Adult
Biological and medical sciences
Blood
Chelating Agents - administration & dosage
Chelating Agents - adverse effects
Chelating Agents - therapeutic use
Chemical and industrial products toxicology. Toxic occupational diseases
Hematology
Humans
Lead - blood
Lead - urine
Lead Poisoning - blood
Lead Poisoning - drug therapy
Lead Poisoning - urine
Male
Medical sciences
Metals and various inorganic compounds
Occupational Diseases - blood
Occupational Diseases - drug therapy
Occupational Diseases - urine
Succimer - administration & dosage
Succimer - adverse effects
Succimer - therapeutic use
Toxicology
Trace elements
Treatment Outcome
Urinalysis
Urine
Workers
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) was evaluated in workers occupationally exposed to lead (Pb; blood level >50 mg //dL). Ten men were given 600 mg of DMSA per orem daily, for five days. Pb concentrations of whole blood and urine were determined throughout therapy. Hematology analyses, blood chemistry, and urinalysis were obtained at the start of the study, at the end of the DMSA treatment, and at 72 hours after the administration of the final dose. DMSA therapy had no influence on hepatic, hematologic, or renal functions and was effective in decreasing the concentration of blood Pb in all the subjects without adverse drug reactions.
ISSN:0960-3271
1477-0903
DOI:10.1191/0960327102ht280oa